CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Feb. 20, 2020—Thermo Fisher Scientific and NanoPin Technologies have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography-mass spectrometry–based workflows.
Through the detection of disease-related antigens directly from patient blood samples, NanoPin’s diagnostic platform using Thermo Fisher’s LC-MS technology will lead to the development of sensitive clinical assays for infectious disease, which aim to reduce time to results, determine infection stage, and monitor patient response to prescribed treatment.
Pages: 1 2